About

Deepcell specializes in biotechnology focused on cell analysis and sorting. The main product, the REM-I platform, utilizes label-free imaging and deep learning to analyze and categorize cells based on their shape and structure. This technology provides detailed data about individual cells through advanced microfluidics and artificial intelligence, allowing for comprehensive cell characterization. Clients include pharmaceutical companies and academic researchers who require precise cell analysis for drug development and disease studies. Deepcell differentiates itself by combining microfluidics, AI, and data analytics, making its REM-I platform a valuable tool in scientific and medical research. The company's goal is to enhance cell analysis capabilities for researchers, providing insights that can lead to advancements in healthcare and science.

Simplify's Take

What believers are saying

• Deepcell is raising $80M to expand and accelerate product development.
• Demand for label-free imaging technologies is increasing, aligning with Deepcell's offerings.
• AI in translational research is expanding, enhancing Deepcell's value proposition.

What critics are saying

• Emerging competition from companies like Berkeley Lights could impact Deepcell's market share.
• Rapid technological advancements may require costly updates to Deepcell's REM-I platform.
• Potential ethical concerns and regulatory scrutiny could slow product adoption.

What makes Deepcell unique

• Deepcell's REM-I platform combines label-free imaging with deep learning for cell analysis.
• The company uses advanced microfluidics for precise cell sorting and analysis.
• Deepcell's AI-driven technology provides high-dimensional quantitative readouts of individual cells.

Help us improve and share your feedback! Did you find this helpful?

YesNo